Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.

Behm DJ, Aiyar NV, Olzinski AR, McAtee JJ, Hilfiker MA, Dodson JW, Dowdell SE, Wang GZ, Goodman KB, Sehon CA, Harpel MR, Willette RN, Neeb MJ, Leach CA, Douglas SA.

Br J Pharmacol. 2010 Sep;161(1):207-28. doi: 10.1111/j.1476-5381.2010.00889.x.

2.

Renal impairment, hypertension and plasma urotensin II.

Mosenkis A, Kallem RR, Danoff TM, Aiyar N, Bazeley J, Townsend RR.

Nephrol Dial Transplant. 2011 Feb;26(2):609-14. doi: 10.1093/ndt/gfq416. Epub 2010 Jul 9.

3.

Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists.

Thalji RK, Aiyar N, Davenport EA, Erhardt JA, Kallal LA, Morrow DM, Senadhi S, Burns-Kurtis CL, Marino JP Jr.

Bioorg Med Chem Lett. 2010 Jul 15;20(14):4104-7. doi: 10.1016/j.bmcl.2010.05.072. Epub 2010 Jun 9.

PMID:
20542694
4.

Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.

Willette RN, Eybye ME, Olzinski AR, Behm DJ, Aiyar N, Maniscalco K, Bentley RG, Coatney RW, Zhao S, Westfall TD, Doe CP.

J Pharmacol Exp Ther. 2009 Sep;330(3):964-70. doi: 10.1124/jpet.109.154443. Epub 2009 Jun 25.

5.

Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists.

Morales-Ramos AI, Mecom JS, Kiesow TJ, Graybill TL, Brown GD, Aiyar NV, Davenport EA, Kallal LA, Knapp-Reed BA, Li P, Londregan AT, Morrow DM, Senadhi S, Thalji RK, Zhao S, Burns-Kurtis CL, Marino JP Jr.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6222-6. doi: 10.1016/j.bmcl.2008.09.102. Epub 2008 Oct 2.

PMID:
18926700
6.

Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.

Behm DJ, McAtee JJ, Dodson JW, Neeb MJ, Fries HE, Evans CA, Hernandez RR, Hoffman KD, Harrison SM, Lai JM, Wu C, Aiyar NV, Ohlstein EH, Douglas SA.

Br J Pharmacol. 2008 Oct;155(3):374-86. doi: 10.1038/bjp.2008.266. Epub 2008 Jun 30.

7.

Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.

Jin J, An M, Sapienza A, Aiyar N, Naselsky D, Sarau HM, Foley JJ, Salyers KL, Knight SD, Keenan RM, Rivero RA, Dhanak D, Douglas SA.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3950-4. doi: 10.1016/j.bmcl.2008.06.019. Epub 2008 Jun 10.

PMID:
18573659
8.

Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.

McAtee JJ, Dodson JW, Dowdell SE, Erhard K, Girard GR, Goodman KB, Hilfiker MA, Jin J, Sehon CA, Sha D, Shi D, Wang F, Wang GZ, Wang N, Wang Y, Viet AQ, Yuan CC, Zhang D, Aiyar NV, Behm DJ, Carballo LH, Evans CA, Fries HE, Nagilla R, Roethke TJ, Xu X, Douglas SA, Neeb MJ.

Bioorg Med Chem Lett. 2008 Jul 1;18(13):3716-9. doi: 10.1016/j.bmcl.2008.05.058. Epub 2008 May 20.

PMID:
18524591
9.

Development of potent and selective small-molecule human Urotensin-II antagonists.

McAtee JJ, Dodson JW, Dowdell SE, Girard GR, Goodman KB, Hilfiker MA, Sehon CA, Sha D, Wang GZ, Wang N, Viet AQ, Zhang D, Aiyar NV, Behm DJ, Carballo LH, Evans CA, Fries HE, Nagilla R, Roethke TJ, Xu X, Yuan CC, Douglas SA, Neeb MJ.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3500-3. doi: 10.1016/j.bmcl.2008.05.027. Epub 2008 May 10.

PMID:
18502123
10.

The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.

Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, Shabon U, Bao W, Aiyar N, Yue TL, Brown AJ, Morrison AD, Douglas SA.

Br J Pharmacol. 2007 Nov;152(5):825-31. Epub 2007 Aug 20.

11.

GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.

Hicks A, McCafferty GP, Riedel E, Aiyar N, Pullen M, Evans C, Luce TD, Coatney RW, Rivera GC, Westfall TD, Hieble JP.

J Pharmacol Exp Ther. 2007 Oct;323(1):202-9. Epub 2007 Jul 12.

12.

Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor.

Johns DG, Ao Z, Heidrich BJ, Hunsberger GE, Graham T, Payne L, Elshourbagy N, Lu Q, Aiyar N, Douglas SA.

Biochem Biophys Res Commun. 2007 Jun 22;358(1):145-9. Epub 2007 Apr 19.

PMID:
17475216
13.

Human urotensin II in the plasma of anephric subjects.

Mosenkis A, Danoff TM, Aiyar N, Bazeley J, Townsend RR.

Nephrol Dial Transplant. 2007 Apr;22(4):1269-70. Epub 2006 Nov 28. No abstract available.

PMID:
17132703
14.

Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells.

Aiyar N, Disa J, Ao Z, Ju H, Nerurkar S, Willette RN, Macphee CH, Johns DG, Douglas SA.

Mol Cell Biochem. 2007 Jan;295(1-2):113-20. Epub 2006 Aug 8.

PMID:
16896535
15.

The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Behm DJ, Stankus G, Doe CP, Willette RN, Sarau HM, Foley JJ, Schmidt DB, Nuthulaganti P, Fornwald JA, Ames RS, Lambert DG, Calo' G, Camarda V, Aiyar NV, Douglas SA.

Br J Pharmacol. 2006 May;148(2):173-90.

16.

Urotensin-II levels in acute coronary syndromes.

Joyal D, Huynh T, Aiyar N, Guida B, Douglas S, Giaid A.

Int J Cardiol. 2006 Mar 22;108(1):31-5.

PMID:
16516696
17.

Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography.

Disa J, Floyd LE, Edwards RM, Douglas SA, Aiyar NV.

Peptides. 2006 Jun;27(6):1532-7. Epub 2005 Nov 14.

PMID:
16290260
18.

Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle.

Behm DJ, Ao Z, Camarda V, Aiyar NV, Johns DG, Douglas SA.

Eur J Pharmacol. 2005 Jun 15;516(3):276-81.

PMID:
15975570
19.

Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.

Jin J, Dhanak D, Knight SD, Widdowson K, Aiyar N, Naselsky D, Sarau HM, Foley JJ, Schmidt DB, Bennett CD, Wang B, Warren GL, Moore ML, Keenan RM, Rivero RA, Douglas SA.

Bioorg Med Chem Lett. 2005 Jul 1;15(13):3229-32.

PMID:
15936190
20.

Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Douglas SA, Behm DJ, Aiyar NV, Naselsky D, Disa J, Brooks DP, Ohlstein EH, Gleason JG, Sarau HM, Foley JJ, Buckley PT, Schmidt DB, Wixted WE, Widdowson K, Riley G, Jin J, Gallagher TF, Schmidt SJ, Ridgers L, Christmann LT, Keenan RM, Knight SD, Dhanak D.

Br J Pharmacol. 2005 Jul;145(5):620-35.

21.

Cloning and pharmacological characterization of the cat urotensin-II receptor (UT).

Aiyar N, Johns DG, Ao Z, Disa J, Behm DJ, Foley JJ, Buckley PT, Sarau HM, van-der-Keyl HK, Elshourbagy NA, Douglas SA.

Biochem Pharmacol. 2005 Apr 1;69(7):1069-79.

PMID:
15763543
22.

Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking.

Bomberger JM, Parameswaran N, Hall CS, Aiyar N, Spielman WS.

J Biol Chem. 2005 Mar 11;280(10):9297-307. Epub 2004 Dec 21.

23.

Neuromedin U elicits cytokine release in murine Th2-type T cell clone D10.G4.1.

Johnson EN, Appelbaum ER, Carpenter DC, Cox RF, Disa J, Foley JJ, Ghosh SK, Naselsky DP, Pullen MA, Sarau HM, Scheff SR, Steplewski KM, Zaks-Zilberman M, Aiyar N.

J Immunol. 2004 Dec 15;173(12):7230-8.

24.

Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.

Johns DG, Ao Z, Naselsky D, Herold CL, Maniscalco K, Sarov-Blat L, Steplewski K, Aiyar N, Douglas SA.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Oct;370(4):238-50. Epub 2004 Sep 30.

PMID:
15549273
25.

Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assays.

Aiyar N, Guida B, Ao Z, Disa J, Naselsky D, Behm DJ, Su JL, Kull FC Jr, Douglas SA.

Peptides. 2004 Aug;25(8):1339-47.

PMID:
15350702
26.

Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells.

Aiyar N, Disa J, Foley JJ, Buckley PT, Wixted WE, Pullen M, Shabon U, Dul E, Szekeres PG, Elshourbagy NA, Sarau HM, Appelbaum E, Bolaky J.

Pharmacology. 2004 Sep;72(1):33-41.

PMID:
15292653
27.

Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines.

Douglas SA, Naselsky D, Ao Z, Disa J, Herold CL, Lynch F, Aiyar NV.

Br J Pharmacol. 2004 Jul;142(6):921-32. Epub 2004 Jun 21.

28.

Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats.

Gartlon J, Szekeres P, Pullen M, Sarau HM, Aiyar N, Shabon U, Michalovich D, Steplewski K, Ellis C, Elshourbagy N, Duxon M, Ashmeade TE, Harrison DC, Murdock P, Wilson S, Ennaceur A, Atkins A, Heidbreder C, Hagan JJ, Hunter AJ, Jones DN.

Psychopharmacology (Berl). 2004 Dec;177(1-2):1-14. Epub 2004 Jun 16.

PMID:
15205870
29.

Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.

Behm DJ, Herold CL, Camarda V, Aiyar NV, Douglas SA.

Eur J Pharmacol. 2004 May 25;492(2-3):113-6.

PMID:
15178353
30.

G protein-coupled receptors in drug discovery.

Nambi P, Aiyar N.

Assay Drug Dev Technol. 2003 Apr;1(2):305-10. Review.

PMID:
15090195
31.

Production and characterization of monoclonal antibodies against the vasoconstrictive peptide human urotensin-II.

Su JL, Ao Z, Aiyar NV, Ellis B, Martin JD, Douglas SA, Kull FC Jr.

Hybrid Hybridomics. 2003 Dec;22(6):377-82.

PMID:
14683597
32.

Molecular cloning and pharmacological characterization of bovine calcitonin receptor-like receptor from bovine aortic endothelial cells.

Aiyar N, Disa J, Ao Z, Xu D, Surya A, Pillarisetti K, Parameswaran N, Gupta SK, Douglas SA, Nambi P.

Biochem Pharmacol. 2002 Jun 1;63(11):1949-59.

PMID:
12093471
33.

Bucindolol displays intrinsic sympathomimetic activity in human myocardium.

Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, Ohlstein EH, Bishopric NH.

Circulation. 2002 May 21;105(20):2429-34.

34.

Novel regulation of adrenomedullin receptor by PDGF: role of receptor activity modifying protein-3.

Nowak W, Parameswaran N, Hall CS, Aiyar N, Sparks HV, Spielman WS.

Am J Physiol Cell Physiol. 2002 Jun;282(6):C1322-31.

35.

Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey.

Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, Ao Z, Maleeff BE, Naselsky D, Disa J, Aiyar NV.

Br J Pharmacol. 2002 May;136(1):9-22.

36.
37.

Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.

Willette RN, Anderson KM, Nelson AH, Olzinski AR, Woods T, Coatney RW, Aiyar N, Ohlstein EH, Barone FC.

J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17.

PMID:
11588531
39.
40.

Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist.

Aiyar N, Daines RA, Disa J, Chambers PA, Sauermelch CF, Quiniou M, Khandoudi N, Gout B, Douglas SA, Willette RN.

J Pharmacol Exp Ther. 2001 Mar;296(3):768-75.

41.

A G protein-coupled receptor for UDP-glucose.

Chambers JK, Macdonald LE, Sarau HM, Ames RS, Freeman K, Foley JJ, Zhu Y, McLaughlin MM, Murdock P, McMillan L, Trill J, Swift A, Aiyar N, Taylor P, Vawter L, Naheed S, Szekeres P, Hervieu G, Scott C, Watson JM, Murphy AJ, Duzic E, Klein C, Bergsma DJ, Wilson S, Livi GP.

J Biol Chem. 2000 Apr 14;275(15):10767-71.

42.

Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey.

Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN.

Br J Pharmacol. 2000 Dec;131(7):1262-74.

43.

Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate.

Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NV, Willette RN.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S163-6.

PMID:
11078367
44.

Desensitization and resensitization of adrenomedullin-sensitive receptor in rat mesangial cells.

Parameswaran N, Aiyar N, Wu H, Brooks DP, Nambi P, Spielman WS.

Eur J Pharmacol. 2000 Nov 3;407(3):205-10.

PMID:
11068015
45.
46.

Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure.

Behr TM, Wang X, Aiyar N, Coatney RW, Li X, Koster P, Angermann CE, Ohlstein E, Feuerstein GZ, Winaver J.

Circulation. 2000 Sep 12;102(11):1315-22.

47.

Involvement of G protein-coupled receptor kinase-6 in desensitization of CGRP receptors.

Aiyar N, Disa J, Dang K, Pronin AN, Benovic JL, Nambi P.

Eur J Pharmacol. 2000 Sep 1;403(1-2):1-7.

PMID:
10969137
48.

Vasodilatory effect of adrenomedullin in mouse aorta.

Ashton D, Hieble P, Gout B, Aiyar N.

Pharmacology. 2000 Aug;61(2):101-5.

PMID:
10940784
49.

Activation of multiple mitogen-activated protein kinases by recombinant calcitonin gene-related peptide receptor.

Parameswaran N, Disa J, Spielman WS, Brooks DP, Nambi P, Aiyar N.

Eur J Pharmacol. 2000 Feb 18;389(2-3):125-30.

PMID:
10688975
50.

Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.

Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA.

Nature. 1999 Sep 16;401(6750):282-6. Erratum in: Nature 1999 Dec 23-30;402(6764):898.

PMID:
10499587

Supplemental Content

Support Center